• OUTLOOK ARENA
  • VIEWS ON NEWS
  • APRIL 5, 2002

E.Merck: Healthy performance

E.Merck (India), the subsidiary of the German multinational Merck, reported encouraging numbers for the year ended Dec' 01 (FY02). A topline growth of 8% reported by the company is comparatively better than the performance of other MNC pharma peers. Both sales and operating margins improved on the back of upward price revision and relaunch of its vitamin brand Neurobion in June 2000.

(Rs m) FY01 FY02 %Change
Sales 3,134 3,385 8.0%
Other Income 67 85 26.2%
Expenditure 2,582 2,736 6.0%
Operating Profit (EBDIT) 552 649 17.5%
Operating Profit Margin (%) 17.6% 19.2%
Interest 23 6 -75.8%
Depreciation 72 95 30.8%
Profit before Tax 524 633 20.8%
Tax 139 186 34.3%
Profit after Tax/(Loss) 385 447 16.0%
Net profit margin (%) 12.3% 13.2%  
No. of Shares (eoy) (m) 17 17  
Diluted Earnings per share* 22.9 26.5  
P/E (at current price)   12  
(*- annualised)      

E. Merck is a market leader in vitamins and derives over 60% of its turnover from this segment. Three of its vitamin brands Evion, Neurobion and Polybion contribute almost 40% of the company’s turnover. During the first half of the current year the company re-introduced Neurobin with better marketing focus. However, the pharma division showed a sluggish growth of 3% mainly on account of competition from generic players. The slow growth in pharma division was more than compensated by a 20% growth in non-pharma division comprising laboratory and speciality chemicals.

The stock price of the company took a beating last year due to the fact that the government banned manufacture/ marketing of fixed combination of Vitamin B1, B6 and B12 (Neurobin). Besides, the government has been tinkering with this segment with steep price reductions. Such price reductions affected `Polybion`. Coupled with this, the vitamin segment as a whole was not logging any attractive growth rates. As a result, the company had to rework its business strategy by changing formulations and launching `Neurobion Forte`. Further, to overcome the high price volatility in Vitamin E due to fierce competition from Chinese and European suppliers the company is evaluating various options like better utilisation of plant capacity and outsourcing of ingredients.

At the current market price of Rs 325, the stock trades at 12x FY02 earnings. After hitting a low of Rs 240, from a high of Rs 460, the stock price of the company has witnessed a sharp correction in the last few days. The optimism seems to be due to the recent DPCO dilution with most of the vitamin brands coming out of DPCO. E. Merck derives around 60% of its revenues from the vitamin segment. The upsurge in the stock price currently has been on the back of encouraging performance and DPCO expectations. As per the indications, the company has recorded good sale numbers even in the first two months of the current year. However, the product portfolio of the company is still very concentrated and valuations going forward would depend on the success in new therapeutic areas ventured into by the company.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407